Ecamsule

Summary

Ecamsule (CHEMBL3989850) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 562.7 Da · C28H34O8S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989850
Name	Ecamsule
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	146382
Molecular formula	C28H34O8S2
Molecular weight	562.7
InChIKey	HEAHZSUCFKFERC-UHFFFAOYSA-N

SMILES: CC1(C2CCC1(C(=O)C2=CC3=CC=C(C=C3)C=C4C5CCC(C4=O)(C5(C)C)CS(=O)(=O)O)CS(=O)(=O)O)C

IUPAC name: [3-[[4-[[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid

Also known as: Ecamsul, Ecamsule, Ecamsule component of anthelios sx, Ecamsule component of capital soleil, Ecamsule solution, Mexoryl, Mexoryl sx, NSC-760054, ECAMSULE

Parent form; salt/anhydrous children: CHEMBL4303168

Patent coverage: 1,073 distinct patent families (2,098 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).